OPEN ACCESS Freely available online

Journal of Genetic Syndromes & Gene Therapy

Perspective

The Role of *UBE3A* in Angelman Syndrome: Insights and Therapeutic Opportunities

Joseph Judson*

Department of Genetics and Genomic Medicine, Rush University Medical Center, Chicago, USA

INTRODUCTION

Angelman Syndrome (AS) is a neurodevelopmental disorder characterized by severe developmental delays, speech impairment, movement disorders, and a distinctive behavioral profile that includes laughter and excitability. The condition primarily arises from the loss of function of the *UBE3A* gene, located on chromosome 15. Understanding the role of *UBE3A* in the pathogenesis of AS provides insights into potential therapeutic strategies aimed at alleviating the symptoms and enhancing the quality of life for affected individuals.

UBE3A is an E3 ubiquitin ligase that plays a crucial role in protein degradation and regulation. In individuals with AS, the paternal allele of *UBE3A* is typically imprinted, meaning it is silenced in neurons, while the maternal allele is dysfunctional due to various genetic alterations, such as deletions, mutations, or uniparental disomy. This results in a complete lack of *UBE3A* expression in the brain, leading to the characteristic symptoms of AS.

Research has demonstrated that *UBE3A* is essential for synaptic function, neuronal development, and plasticity. Its absence disrupts these critical processes, contributing to the cognitive and motor deficits observed in individuals with AS. Understanding these mechanisms not only sheds light on the pathology of AS but also opens avenues for targeted therapeutic interventions.

DESCRIPTION

Insights into *UBE3A* function

Recent studies have elucidated several key functions of *UBE3A* that are relevant to AS:

Synaptic regulation: *UBE3A* is involved in the degradation of specific proteins that regulate synaptic strength and plasticity. Its absence leads to abnormal synaptic transmission and impaired Long-Term Potentiation (LTP), which is crucial for learning and memory.

Dendritic development: *UBE3A* is essential for the proper formation of dendritic spines, which are critical for synaptic connections. Deficits in dendritic structure have been linked to the cognitive impairments seen in AS.

Neuroinflammation: Recent evidence suggests that *UBE3A* may also play a role in regulating neuroinflammation, a contributing factor in many neurodevelopmental disorders, including AS. Dysfunction in *UBE3A* can lead to increased inflammatory responses that may exacerbate neuronal damage.

Therapeutic opportunities

Given the critical role of *UBE3A* in the pathophysiology of Angelman syndrome, several therapeutic strategies are being explored to restore its function or compensate for its absence.

Gene therapy: One of the most promising avenues is the use of gene therapy to reactivate the paternal allele of *UBE3A*. Techniques such as CRISPR/Cas9 and other genome-editing technologies hold potential for targeted interventions. Early studies in animal models have shown that reactivation of the paternal *UBE3A* gene can ameliorate behavioral and cognitive deficits. Although still in the experimental stages, these approaches pave the way for future clinical trials.

***UBE3A* activators:** Researchers are investigating small molecules that can upregulate the expression of *UBE3A* from the paternal allele. For example, compounds like 4-phenylbutyrate (4-PBA) and others are being tested for their ability to promote *UBE3A* expression in neurons. Preclinical studies indicate that these agents can enhance synaptic function and improve behavioral outcomes in animal models of AS.

Antisense Oligonucleotides (ASOs): Another innovative strategy involves the use of ASOs to selectively target and silence the imprinted allele of *UBE3A* in neurons. By reducing the expression of the paternal *UBE3A*, it may be possible to reactivate the silenced maternal allele. This approach could help restore *UBE3A* levels in the brain and improve synaptic function.

Correspondence to: Joseph Judson, Department of Genetics and Genomic Medicine, Rush University Medical Center, Chicago, USA; E-mail: Jospehjd@gmail.com

Received: 28-Oct-2024, Manuscript No. JGSGT-24-34867; **Editor assigned:** 02-Nov-2024, PreQC No. JGSGT-24-34867 (PQ); **Reviewed:** 16-Nov-2024, QC No. JGSGT-24-34867; **Revised:** 13-Jun-2025, Manuscript No. JGSGT-24-34867 (R); **Published:** 20-Jun-2025, DOI: 10.35248/2157-7412.25.16.462

Citation: Judson J (2025) The Role of *UBE3A* in Angelman Syndrome: Insights and Therapeutic Opportunities. J Genet Syndr Gene Ther. 16:462.

Behavioral and supportive therapies: While genetic therapies are being developed, behavioral interventions remain vital in managing AS. Early intervention programs that focus on speech, occupational, and physical therapy can significantly enhance the developmental trajectory of affected individuals. Supportive therapies that address specific behavioral challenges, such as anxiety and sleep disturbances, are also critical components of comprehensive care.

Neuroinflammation modulation: Given the emerging role of *UBE3A* in neuroinflammation, therapies aimed at reducing inflammation in the central nervous system may also be beneficial. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and other anti-inflammatory agents are being explored for their potential to improve neurological outcomes in AS.

Challenges and considerations

While the prospects for targeting *UBE3A* in Angelman syndrome are promising, several challenges remain. The complexity of the *UBE3A* gene and its regulatory mechanisms necessitates further research to fully understand the implications of reactivating or compensating for its function. Moreover, safety and efficacy must be rigorously evaluated in preclinical and clinical studies to ensure that any new therapies do not inadvertently lead to adverse effects.

Ethical considerations also play a crucial role in the development of genetic therapies. Issues surrounding informed consent, especially when involving children, as well as the long-term implications of gene editing, must be carefully navigated. Engaging with the community of individuals with AS and their families will be essential in guiding the development and implementation of these therapies.

CONCLUSION

The role of *UBE3A* in Angelman syndrome provides critical insights into the underlying mechanisms of this complex disorder. As research continues to uncover the multifaceted functions of *UBE3A*, a range of therapeutic opportunities emerges, from gene therapy and small molecule activators to behavioral interventions.

While challenges remain, the advances in understanding *UBE3A*'s role in AS represent a significant step toward developing targeted therapies that can enhance the quality of life for individuals affected by this condition. The collaborative efforts of researchers, clinicians, and families will be instrumental in translating these insights into effective treatments, ultimately fostering a brighter future for those living with Angelman syndrome.